Century Therapeutics, Inc.
IPSC
$2.44
$0.146.09%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 0.00 | -- | -- | 109.16M | 4.17M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.00 | -- | -- | 109.16M | 4.17M |
| Cost of Revenue | 19.70M | 22.53M | 26.86M | 26.58M | 29.38M |
| Gross Profit | -19.70M | -22.53M | -26.86M | 82.58M | -25.20M |
| SG&A Expenses | 5.88M | 6.84M | 7.81M | 8.41M | 8.00M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 25.57M | 29.36M | 34.66M | 34.99M | 37.38M |
| Operating Income | -25.57M | -29.36M | -34.66M | 74.18M | -33.20M |
| Income Before Tax | -19.24M | -34.42M | -32.54M | 76.56M | -34.30M |
| Income Tax Expenses | -68.00K | -- | -- | -- | 1.78M |
| Earnings from Continuing Operations | -19.17M | -34.42M | -32.54M | 76.56M | -36.07M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -19.17M | -34.42M | -32.54M | 76.56M | -36.07M |
| EBIT | -25.57M | -29.36M | -34.66M | 74.18M | -33.20M |
| EBITDA | -22.02M | -26.23M | -31.46M | 77.40M | -29.88M |
| EPS Basic | -0.22 | -0.40 | -0.38 | 0.89 | -0.42 |
| Normalized Basic EPS | -0.17 | -0.20 | -0.24 | 0.56 | -0.22 |
| EPS Diluted | -0.22 | -0.40 | -0.38 | 0.89 | -0.43 |
| Normalized Diluted EPS | -0.17 | -0.20 | -0.24 | 0.56 | -0.22 |
| Average Basic Shares Outstanding | 87.29M | 86.46M | 86.24M | 86.02M | 85.41M |
| Average Diluted Shares Outstanding | 87.29M | 86.46M | 86.24M | 86.10M | 85.41M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |